{"title":"老年高血压的血压目标、用药考虑和特殊关注:关注动脉粥样硬化性心血管疾病、心房颤动、心力衰竭和主动脉狭窄。","authors":"Ru-Yin Hsu, Hao-Yun Lo, Chien-Hao Chen, Yee-Jen Wu, Ding-Cheng Chan, Chih-Cheng Wu, Tzung-Dau Wang, Hsien-Li Kao, Wen-Jung Sun, Yen-Hung Lin, Hung-Ju Lin","doi":"10.1016/j.jfma.2025.05.007","DOIUrl":null,"url":null,"abstract":"<p><p>The management of hypertension in the elderly, particularly concerning atherosclerotic cardiovascular disease (ASCVD) and comorbidities, is crucial given its prevalence and impact on morbidity and mortality. It is important to individualize pharmacotherapy in elderly patients, including basing the dose on age-related changes in organ function and drug pharmacokinetics. In elderly patients with hypertension and ASCVD, despite slight differences among guideline recommendations, the emphasis is on achieving a systolic blood pressure (BP) < 130 mmHg. The optimal target for patients with atrial fibrillation remains under debate, with suggestions ranging from <130/80 mmHg to <140/90 mmHg. The role of anticoagulation treatment further complicates BP management in these patients. BP targets also differ among guidelines regarding heart failure in the elderly, although maintaining systolic BP < 140/90 mmHg is generally advocated. In hypertensive elderly patients with aortic stenosis, the optimal BP targets are even less clear, and should consider the risks of adverse outcomes. Overall, individualized treatment plans considering age, comorbidities, and tolerability are paramount. Further research is warranted to elucidate optimal BP targets and pharmacotherapeutic strategies tailored to the elderly.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.\",\"authors\":\"Ru-Yin Hsu, Hao-Yun Lo, Chien-Hao Chen, Yee-Jen Wu, Ding-Cheng Chan, Chih-Cheng Wu, Tzung-Dau Wang, Hsien-Li Kao, Wen-Jung Sun, Yen-Hung Lin, Hung-Ju Lin\",\"doi\":\"10.1016/j.jfma.2025.05.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The management of hypertension in the elderly, particularly concerning atherosclerotic cardiovascular disease (ASCVD) and comorbidities, is crucial given its prevalence and impact on morbidity and mortality. It is important to individualize pharmacotherapy in elderly patients, including basing the dose on age-related changes in organ function and drug pharmacokinetics. In elderly patients with hypertension and ASCVD, despite slight differences among guideline recommendations, the emphasis is on achieving a systolic blood pressure (BP) < 130 mmHg. The optimal target for patients with atrial fibrillation remains under debate, with suggestions ranging from <130/80 mmHg to <140/90 mmHg. The role of anticoagulation treatment further complicates BP management in these patients. BP targets also differ among guidelines regarding heart failure in the elderly, although maintaining systolic BP < 140/90 mmHg is generally advocated. In hypertensive elderly patients with aortic stenosis, the optimal BP targets are even less clear, and should consider the risks of adverse outcomes. Overall, individualized treatment plans considering age, comorbidities, and tolerability are paramount. Further research is warranted to elucidate optimal BP targets and pharmacotherapeutic strategies tailored to the elderly.</p>\",\"PeriodicalId\":17305,\"journal\":{\"name\":\"Journal of the Formosan Medical Association\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Formosan Medical Association\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jfma.2025.05.007\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Formosan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jfma.2025.05.007","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.
The management of hypertension in the elderly, particularly concerning atherosclerotic cardiovascular disease (ASCVD) and comorbidities, is crucial given its prevalence and impact on morbidity and mortality. It is important to individualize pharmacotherapy in elderly patients, including basing the dose on age-related changes in organ function and drug pharmacokinetics. In elderly patients with hypertension and ASCVD, despite slight differences among guideline recommendations, the emphasis is on achieving a systolic blood pressure (BP) < 130 mmHg. The optimal target for patients with atrial fibrillation remains under debate, with suggestions ranging from <130/80 mmHg to <140/90 mmHg. The role of anticoagulation treatment further complicates BP management in these patients. BP targets also differ among guidelines regarding heart failure in the elderly, although maintaining systolic BP < 140/90 mmHg is generally advocated. In hypertensive elderly patients with aortic stenosis, the optimal BP targets are even less clear, and should consider the risks of adverse outcomes. Overall, individualized treatment plans considering age, comorbidities, and tolerability are paramount. Further research is warranted to elucidate optimal BP targets and pharmacotherapeutic strategies tailored to the elderly.
期刊介绍:
Journal of the Formosan Medical Association (JFMA), published continuously since 1902, is an open access international general medical journal of the Formosan Medical Association based in Taipei, Taiwan. It is indexed in Current Contents/ Clinical Medicine, Medline, ciSearch, CAB Abstracts, Embase, SIIC Data Bases, Research Alert, BIOSIS, Biological Abstracts, Scopus and ScienceDirect.
As a general medical journal, research related to clinical practice and research in all fields of medicine and related disciplines are considered for publication. Article types considered include perspectives, reviews, original papers, case reports, brief communications, correspondence and letters to the editor.